Acumen Pharmaceuticals (ABOS), Monday reported that using a plasma pTau217 screening assay in its Phase?2 ALTITUDE-AD study of sabirnetug reduced trial screening costs by about 40 percent across U.S. and Canadian sites.
Nearly half of volunteers met the pTau217 threshold for confirmatory testing, and 81 percent of those were amyloid-positive minimizing unnecessary PET scans and lumbar punctures and speeding enrollment.
In nonclinical comparisons, sabirnetug demonstrated the strongest binding to toxic amyloid-ß oligomers and minimal affinity for monomers showing an 8,750-fold selectivity for Aß1-42 oligomers over Aß1-40 monomers, outperforming lecanemab and aducanumab.
ABOS is currently trading at $1.53, down $0.0352 or 2.24 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.